Literature DB >> 1480773

The effect of treatment duration in the local control of cervix cancer.

A Fyles1, T J Keane, M Barton, J Simm.   

Abstract

A significant effect of treatment duration on pelvic control was found in 830 patients with cervix cancer treated by radical radiation therapy. Using three methods of analysis, the loss of control consistently approximated 1% per day of treatment prolongation beyond 30 days, although analysis of stage subgroups showed that this effect was predominantly manifested in Stages III/IV compared with Stages I/II. In multivariate analyses using both a logistic regression and a Cox regression model, stage (p = 0.0001 for Stage I/IIA and 0.0036 for Stage IIB relative to Stage III/IV) treatment time (p = 0.0001), and age (p = 0.0067) were independently correlated with pelvic control. Exclusion from analysis of patients with delays due to tumour or treatment related complications, intercurrent illness or manifestations of poor tumour response did not significantly change the magnitude of the time effect nor the ranking of the significant covariates. These results are consistent with the occurrence of accelerated repopulation and warrant further investigation, preferably in a randomized trial of accelerated versus conventionally fractionated radiation therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1480773     DOI: 10.1016/0167-8140(92)90247-r

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  49 in total

1.  Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays.

Authors:  M Maciá I Garau; J Solé Monné; M J Cambra Serés; C Monfà Binefa; M Peraire Llopis
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

2.  Evaluation of the response of concurrent high dose rate intracavitary brachytherapy with external beam radiotherapy in management of early stage carcinoma cervix.

Authors:  Arvind Kumar Patidar; H S Kumar; Rahul V Walke; Pushpendra H Hirapara; Shankar Lal Jakhar; M R Bardia
Journal:  J Obstet Gynaecol India       Date:  2012-08-17

3.  Pure accelerated radiation versus concomitant chemoradiation in selected cases of locally advanced carcinoma cervix: a prospective study.

Authors:  Chhaya Roy; Krishnangshu Bhanja Choudhury; Madhumay Pal; Kakali Chowdhury; Ansuman Ghosh
Journal:  J Obstet Gynaecol India       Date:  2012-09-27

Review 4.  Radiobiological considerations in combining doses from external beam radiotherapy and brachytherapy for cervical cancer.

Authors:  Ana M Tornero-López; Damián Guirado
Journal:  Rep Pract Oncol Radiother       Date:  2018-07-02

5.  Prospective randomized study comparing concomitant chemoradiotherapy using weekly cisplatin & paclitaxel versus weekly cisplatin in locally advanced carcinoma cervix.

Authors:  Pragyat Thakur; Rajeev Seam; Manoj Gupta; Manish Gupta
Journal:  Ann Transl Med       Date:  2016-02

6.  Acute effects of therapeutic irradiation for prostatic carcinoma on anorectal function.

Authors:  E K Yeoh; A Russo; R Botten; R Fraser; D Roos; M Penniment; M Borg; W M Sun
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

7.  Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer : Institutional experiences.

Authors:  Radovan Vojtíšek; Emília Sukovská; Jan Baxa; Marie Budíková; Petra Kovářová; Jindřich Fínek
Journal:  Strahlenther Onkol       Date:  2019-07-15       Impact factor: 3.621

8.  Onset time of tumor repopulation for cervical cancer: first evidence from clinical data.

Authors:  Zhibin Huang; Nina A Mayr; Mingcheng Gao; Simon S Lo; Jian Z Wang; Guang Jia; William T C Yuh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-02       Impact factor: 7.038

9.  A preliminary results of a randomized trial comparing monthly 5-flourouracil and cisplatin to weekly cisplatin alone combined with concurrent radiotherapy for locally advanced cervical cancer.

Authors:  Young Seok Kim; Seong Soo Shin; Eun Kyung Choi; Jong Hoon Kim; Seung Do Ahn; Sang-wook Lee; Heon-Jin Park; Young-Tak Kim; Jung-Eun Mok; Joo-Hyun Nam
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

10.  Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.

Authors:  Leonard L Gunderson; Kathryn A Winter; Jaffer A Ajani; John E Pedersen; Jennifer Moughan; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher G Willett
Journal:  J Clin Oncol       Date:  2012-11-13       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.